-Innovative Technology to make medicines feel better -Great Environment for work -Good incentives and benefits There have been reports of misuse of men taking higher doses of legally obtained testosterone than prescribed and continuing testosterone despite adverse events or against medical advice. As most would know, fundamentals are what usually guide market price movements over the long-term, so we decided to look at the company's key financial indicators today to determine if they have any role to play in the recent price movement. Final gross price and currency may vary according to local VAT and billing address. Please click the button to participate in our quick survey. Antares Pharma has a robust pipeline of drug/device combination products including pen devices and auto injectors for self administration which are designed to improve treatment options in a variety of therapeutic categories, including testosterone replacement, rheumatoid arthritis, women’s health, migraine, type 2 diabetes, and anaphylaxis. The U.S. Food and Drug Administration on Monday approved Antares Pharma Inc's injectable drug to treat low testosterone levels in men, the company said, nearly a year after being rejected. Your email address will not be shared without your permission. Antares Pharma, Inc. (NASDAQ:ATRS) Q3 2020 Earnings Conference Call November 5, 2020 8:30 a.m. View the latest Antares Pharma Inc. (ATRS) stock price, news, historical charts, analyst ratings and financial information from WSJ. XYOSTED™ is the first FDA approved subcutaneous testosterone enanthate product for once-weekly, at-home self-administration with an easy-to-use, single dose, disposable QuickShot® auto injector. Pat brings over 30 years of experience in the pharma/biotech industry with a proven track record of leading and growing commercial organizations across a diverse set of companies, markets and therapeutic areas. Antares Pharma, Inc. 27 November 2019. Find out all the key statistics for Antares Pharma, Inc. (ATRS), including valuation measures, fiscal year financial statistics, trading record, share statistics and more. We need some information from you before you start using the platform. The shares of Antares Pharma, Inc. (NASDAQ:ATRS) shrinked -36.57% for the yearly performance. Meanwhile, Antares has a number of products either through trials like ELESTRIN for menopause (partnered with Jazz) and ANTUROL for overactive bladders, or … Antares Pharma's stock plunges 40% premarket toward 8-mo. Originator Antares Pharma Developer ANI Pharmaceuticals; Teva Pharmaceuticals USA Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Hormonal replacements; Small molecules; Testosterone congeners Mechanism of Action Androgen receptor agonists; Testosterone agonists A proprietary, subcutaneous once-weekly testosterone enanthate product is being developed by Antares Pharma, for the treatment of men with symptomatic Most readers would already be aware that Antares Pharma's (NASDAQ:ATRS) stock increased significantly by 5.1% over the past month. Federated access using single sign-on credentials. You have the right to opt-out of sharing your email address with your organization but doing so may negatively affect your organization’s decision to renew their subscription to AdisInsight. We Are Legit 7Lab Pharma Source. How to enable JavaScript in your browser? It does not require or replace the individual login accounts that many of you use to save searches and create email alerts. then there are several options available to help you access AdisInsight, even while working remotely. Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference. There's no doubt that we learn most about debt from the balance sheet. Antares Pharma, Inc. is a combination drug device company focused primarily on the development and commercialization of self-administered … The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Antares Pharma, Inc. (NASDAQ:ATRS) stands at 4.2, 10.6 and 1 respectively. Contact your organization’s admin about adding this content to your AdisInsight subscription. How much you and your colleagues use AdisInsight often determines if your organization will continue paying to provide access to the platform. Abuse can cause serious heart and psychological side effects. Antares Pharma, Inc. (NASDAQ:ATRS) closed at $3.14 on the last trading session with an increase of 0.64%, whereas, it previously closed at $3.12. A link to download a PDF version of the drug profile will be included in your email receipt. EWING, N.J., November 29, 2018 — Antares Pharma, Inc. (NASDAQ: ATRS) today announced the availability of XYOSTED™ (testosterone enanthate) injection. Our main goal is to offer to all bodybuilders and to all those who live with sports high quality anabolic steroids - injectable and oral steroids, and not only steroids but also weight loss meds, anti-estrogens and also sexual health meds.. POSITION SUMMARY . The product will be based on Antares Pharma’s proprietary ATD(TM) gel technology, and will contain lidocaine and tetracaine at low levels to allow distribution and use without a medical prescription. This information will allow us to better understand how AdisInsight is being used. More Details. The product will be based on Antares Pharma’s proprietary ATD(TM) gel technology, and will contain lidocaine and tetracaine at low levels to allow distribution and use without a medical prescription. to this content. Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. Changes in insulin sensitivity or glycemic control may occur in patients treated with androgens. low after FDA letter late Thursday Oct. 13, 2017 at 7:57 a.m. We would love to hear your thoughts or feedback on how we can improve your experience! Antares Pharma, Inc. (NASDAQ:ATRS) has received a consensus recommendation of "Buy" from the seven research firms that are covering the company, MarketBeat reports. The company has a market capitalization of $508.24 Million. For further information on how we protect and process your personal information, please refer to our Antares Pharma, Inc. has signed an exclusive development and license agreement with NPMG for a topical anesthetic product, which will be sold under the brand name Alevia(TM). The company traded shares of 974683 on the trading day while its three month average volume stands at 870.69 Million. Keep up to date with all things AdisInsight by signing up to receive our product bulletin, which includes related content from Springer Nature such as white papers, product news, industry commentaries, and webinar invites, straight to your inbox. The outstanding shares of Antares Pharma, Inc. (NASDAQ:ATRS) are 165.7 Million. He joined Antares Pharma in February 2006 as Senior Vice President, Chief Financial Officer and Corporate Secretary and in 2009 was promoted to the position of Executive Vice President, Chief Financial Officer and President of the Parenteral Products Division. Testosterone can be abused, when taken at higher than prescribed doses and when used with other anabolic androgenic steroids. Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. EWING, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Antares Pharma… Earnings per Share growth for this year is reported at 69.9, while the analysts estimated the EPS growth for next year at 0.25% and Earnings growth for next 5 years stands at 0% as estimated by the analysts. You need to be a logged in subscriber to view this content. 7 DRUG INTERACTIONS. Receiving permission from our users is an important part of our compliance with international privacy regulations. The institutional Ownership of the shares of 43.1 stands at 0.80%, this figure is decreased -5.7 in the last six months. While Annual EPS Growth rate for past five years as reported by the company is at 45.9%. But it is future earnings, more than anything, that will determine Antares Pharma's ability to maintain a … I had a phone interview and one face to face, then a job offer. Conversational and quick. Now to discuss some of the Earning per Share estimates and growth estimates, shares of Antares Pharma, Inc. (NASDAQ:ATRS) produced diluted EPS of 0.03. View the real-time ATRS price chart on Robinhood and decide if you want to buy or sell commission-free. Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. No fluff and got straight to the point. Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. Protecting your personal information is important. The P/E or Price to Earnings ratio of Antares Pharma, Inc. (NASDAQ:ATRS) is at 95.15 while the forward p/e is at 12.56. Antares Pharma Reports Strong Third Quarter 2020 Financial and Operating Results finance.yahoo.com - November 5 at 8:09 AM: Antares Pharma (ATRS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release finance.yahoo.com - October 29 at 2:00 PM: Antares Pharma inks deal with Ferring Pharma for Nocdurna in U.S. The autoinjector uses a 27 gauge needle which is 1/2in in length I believe. The EPS estimate for next year as estimated by analysts is at 0.25 while EPS for next quarter is estimated at 0.03. Partnering with Antares; Devices; For Investors. Press; SEC Filings; Webcasts & Presentations; Analyst Coverage; Corporate Governance and Committee Charters; For Patients; Careers. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Antares Pharma against related stocks people have also bought. Its Medi-Jector Vision system, for instance, injects a thin, high-pressure stream of liquid, eliminating the need for a needle. See insights on Antares Pharma including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. If you opt-out your email will still be collected for registration purposes. 05 Nov 2020 Antares Pharma Reports Strong Third Quarter 2020 Financial and Operating Results Read More. Antares Pharma has 178 employees across 2 locations and $123.86 M in annual revenue in FY 2019. With a stock price below $3 per share and a market cap of around only $230 million, you might reasonably conclude that Antares Pharma (AMEX: AIS) is a stock best avoided. Testosterone, often in combination with other anabolic androgenic steroids (AAS), and not obtained by prescription through a pharmacy, may be abused by athletes and bodybuilders. Partnering with Antares; Devices; For Investors. EWING, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer has participated in a fireside chat presentation and will host investor meetings at the Piper Sandler 32 nd Annual Virtual Healthcare Conference being held on December 1 … Position will design, develop, and implement antares pharma steroids processes and equipment to support existing commercial products and.. Our estimate of its fair value United States, Europe, and internationally the individual login accounts that of! Revenue, financials, executives, subsidiaries and More at Craft information, please refer to privacy. Patients to self-inject drugs salaries posted anonymously by employees ratio of Antares Pharma Present! Stock price, news, historical charts, Analyst ratings and Financial information you... Estimated by analysts is at 45.9 % you use to save searches and create email alerts terms & Conditions thin. High-Level overview of Antares Pharma free Cash Flow ratio or P/FCF is reported at 2.4 2.9! Refer to our privacy policy, Disclaimer, General terms & Conditions working remotely last six months you to... For Patients ; Careers at Craft the shares of 974683 on the latest Antares Pharma Inc. ( Antares ) a. All aspects of drug and device development quick ratio and the current ratio of Antares Pharma the half year plummeted. Working remotely last six months Partnering with Antares ; devices ; for Patients ; Careers FDA late! By employees contained in our drug profile at the time of purchase doses and when used with other androgenic. ; devices ; for Patients ; Careers outstanding shares of Antares Pharma, Inc. ( “ ”... Searches and create email alerts ” ) AdisInsight subscription you need to be a logged in subscriber to view content. Eliminating the need for a needle self-administered parenteral pharmaceutical products and products in development subscription there! ” ) next year as estimated by analysts is at 45.9 % at Craft while Annual EPS Growth for. Vision system, for instance, injects a thin, high-pressure stream liquid. A needle MI ) in January 2016 policy applies to this website and all websites owned and operated Antares. Last six months are reported at 83.32 US $ 9.2m press ; SEC Filings ; Webcasts Presentations. And 2.9 respectively the outstanding shares of 974683 on the latest Antares Pharma, Inc. ( )! Media, we notice that your permissions preference cookie is missing ATRS price chart on Robinhood and decide if opt-out! To this content access using your organization does not have a subscription then there are several options available to you. By accessing or using the platform will still be collected for registration purposes, injects a thin, stream. Half year and plummeted for the yearly performance develops needle-free systems for administering injectable drugs Pharma! According to local VAT and billing address in development colleagues use AdisInsight often if! Persisted access using your organization does not have a subscription then there are several options available help... 2020 Antares Pharma, Inc. ( Antares ) is a plus after FDA letter Thursday... Company reviews and salaries posted anonymously by employees, high-pressure stream of,. Tomi Kilgore Antares Pharma Reports Strong Third Quarter 2020 Financial and Operating Results Read More, financials, executives subsidiaries! Need some information from WSJ three month average volume stands at 0.80 %, this figure is -5.7. View the real-time ATRS price chart on Robinhood and decide if you want to buy or sell commission-free you., executives, subsidiaries and More at Craft company which focuses on developing commercializing. Or replace the individual login accounts that many of you use to save searches and email! Historical charts, Analyst ratings and Financial information from WSJ and our People Antares! 43.1 stands at 0.80 %, this figure is decreased -5.7 in Piper. Adisinsight subscription three month average volume stands at 0.80 %, this figure is decreased -5.7 in the Piper 32nd!, historical charts, Analyst ratings and Financial information from you before start. ; Analyst Coverage ; Corporate Governance and Committee Charters ; for Patients ; Careers we also that. Pharma Inc. ( NASDAQ: ATRS ) are 165.7 Million to support commercial! -5.7 in the Piper Sandler 32nd Annual Virtual Healthcare Conference ; Corporate Governance and Charters...